Capecitabine in ER+/HER2-negative Breast Cancer

Clinical trial NCT07631052 · RECRUITING

Trial details

NCT number: NCT07631052
Sponsor: University Health Network, Toronto
Status: RECRUITING
Phase: Phase 2
Study type: INTERVENTIONAL

ER-positive, HER2-negative Breast Cancer Breast Cancer Stage I Breast Cancer Stage II Breast Cancer Stage III

Start date: 2026-07-29
Primary completion: 2029-08-01
Enrollment: 15

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.